Biofrontera Inc. BFRI 深 沪
等待开盘 09-18 09:30:00 美东时间
0.85
-0.021
-2.39%
华盛通- 最 高0.8914
- 今 开0.8914
- 成交量 5.84万股
- 最 低 0.85
- 昨 收 0.8708
- 总市值 906.81万
- 52周最高 2.22
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.536
- 委 比 2.09%
- 总股本 1066.84万
- 历史最高 292.60
- 量 比 0.61
- 振 幅 4.75%
- 历史最低 0.536
- 每 手 1
- 风险率 0.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Biofrontera Completes Treatment Phase In Phase 3 Trial Of Ameluz For Actinic Keratosis On Body; Supplemental New Drug Application Planned For Submission In Q2 2026
All 172 patients have now entered the 12-month follow-up phaseTrial involves larger surface areas, building on the approval in October 2024 for use of up to 3 tubes of Ameluz® per treatmentStudy results expected to
09-16 22:32
Biofrontera shares are trading higher after the company announced that the final patient in its Phase 2b clinical trial evaluating Ameluz for the treatment of moderate to severe acne vulgaris completed participation. The company expects to receive top-line data in Q1 2026 and will present findings to the FDA in Q3 2026 as the basis for a future Phase III program.
Biofrontera shares are trading higher after the company announced that the fina...
08-25 20:29
Biofrontera Q2 EPS $(0.57) Misses $(0.42) Estimate, Sales $9.03M Beat $8.30M Estimate
Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.42) by 35.71 percent. This is a 1040 percent decrease over losses of $(0.05) per share from the
08-14 05:21
Earnings Scheduled For August 13, 2025
Companies Reporting Before The Bell • Evotec (NASDAQ:EVO) is projected to repor...
08-13 16:32
A Look at Biofrontera's Upcoming Earnings Report
Biofrontera (NASDAQ:BFRI) is set to give its latest quarterly earnings report o...
08-13 01:02
Biofrontera Inc. Appoints George Jones as Chief Commercial Officer
Biofrontera Inc. 宣布聘请George Jones为首席商务官，负责掌管公司的商业部门，包括销售、营销和市场准入。此次人事任命紧随公司与Biofrontera AG达成协议收购Ameluz®和RhodoLED®在美国市场的权益，这将显著提升公司的财务状况。Jones拥有超过25年的生物制药行业经验，其丰富的领导和团队建设经验将助力公司在光动力治疗领域进一步扩展。
08-11 20:25
Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025
Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in dermatological products, will report its second-quarter and first-half 2025 financial results on August 13, 2025. A conference call to discuss the results will be held on August 14 at 10:00am ET. The call can be accessed via phone or webcast.
08-04 18:00
Biofrontera Finalizes Acquisition of U.S. Ameluz Rights
Biofrontera ( ($BFRI) ) just unveiled an announcement. On June 30, 2025, Biofro...
07-01 21:15
Biofrontera Completes Strategic Restructuring Agreement
An announcement from Biofrontera ( ($DE:B8FK) ) is now available. Biofrontera A...
07-01 07:58
Biofrontera restructures relationship with Biofrontera AG, backed by $11M investment
Biofrontera (NASDAQ:BFRI) said on Monday that it has acquired all U.S. Rights to Ameluz and RhodoLED from its former parent company Biofrontera AG. An $11M investment led by Rosalind Advisors and AIG...
06-30 20:29
